PD31-07 TESTOSTERONE USE DOES NOT RESULT IN WORSE CARDIOVASCULAR RISK: A LONGITUDINAL EVALUATION OF CARDIOVASCULAR RISK BIOMARKERS

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I1 Apr 2018PD31-07 TESTOSTERONE USE DOES NOT RESULT IN WORSE CARDIOVASCULAR RISK: A LONGITUDINAL EVALUATION OF CARDIOVASCULAR RISK BIOMARKERS John Sigalos, Zachary Dao, Luis Cartagenova, Taylor Kohn, Alexander Pastuszak, and Larry Lipshultz John SigalosJohn Sigalos More articles by this author , Zachary DaoZachary Dao More articles by this author , Luis CartagenovaLuis Cartagenova More articles by this author , Taylor KohnTaylor Kohn More articles by this author , Alexander PastuszakAlexander Pastuszak More articles by this author , and Larry LipshultzLarry Lipshultz More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1538AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Controversy currently exists regarding the cardiovascular (CV) risks of testosterone therapy (TTh). While most studies focus on clinical endpoints such as myocardial infarction, few studies have assessed CV risk using objective biomarkers. METHODS Men presenting to a single academic andrology clinic with either hypogonadal symptoms or on TTh were recruited and underwent CV biomarker testing at baseline and then at follow-up at least 3 months later. Patients were grouped by never on TTh (n=11), new to TTh (n=37), and current TTh use (n=101). A commercial CV biomarker panel included cardiac troponin I (cTnI), endothelin-1 (ET-1), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), interleukin-17A (IL-17A), N-terminal pro-B-type natriuretic peptide (NTproBNP), high-density lipoprotein (HDL), hs C-reactive protein (CRP), hemoglobin A1c (HbA1c), and leptin. Linear regression analysis was performed to control for age, change in testosterone, time between testing, and baseline lab values using the R statistical package. RESULTS In all, 149 men were included with a mean(SD) age of 52(10.0) years and a mean(SD) of 4.8(2.2) months between CV biomarker testing. When controlling for age, change in T, time between testing, and baseline lab values, only a decrease in IL-17A was seen in men either new to TTh or with a history of TTh when compared to those never on TTh. When using categorical values for high risk vs low risk along with pre-determined thresholds, an improvement in NT-probBNP (p=0.05 and 0.02 for new to TTh and current TTh patients, respectively) was observed when compared to men never on TTh. CONCLUSIONS Men who are started on TTh and those maintaining TTh regimens experienced no overall worsening in cardiac biomarkers when compared to hypogonadal men who had not previously been on TTh. For IL-17 and NT-probBNP, improvement in CV risk was observed in men on TTh, further supporting the conclusion that TTh may improve CV risk in hypogonadal men. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e642 Advertisement Copyright & Permissions© 2018MetricsAuthor Information John Sigalos More articles by this author Zachary Dao More articles by this author Luis Cartagenova More articles by this author Taylor Kohn More articles by this author Alexander Pastuszak More articles by this author Larry Lipshultz More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...